our Premium Content: News alerts, weekly reports and conference planners

GENE:

NRAS (Neuroblastoma RAS viral oncogene homolog)

News alerts, weekly reports and conference planners

KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis. (PubMed, Ann Hematol)

Patients with KIT exon 17 mutations tended to harbor an inferior EFS and OS. In conclusion, KIT mutant/CBF-neg AML was a complex subgroup with dismal prognosis and NIT might bring benefits for those patients.

1 day ago

Retrospective data • Journal

NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

Venclexta (venetoclax)

Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability. (PubMed, AIDS)

Together, these results highlight distinct tumorigenic mechanisms in HIV+ DLBCL and underscore the need for mutational profiling of HIV+ DLBCL cohorts worldwide to identify biomarkers and therapeutic targets.

1 day ago

Journal • Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • KMT2D (Lysine Methyltransferase 2D) • MSH2 (MutS Homolog 2) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)

PTEN mutation • ARID1A mutation • NRAS Q61

Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma (clinicaltrials.gov)

P2, N=48, Not yet recruiting, Fudan University

5 days ago

New P2 trial

BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF mutation

Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • iparomlimab (QL1604)

Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer. (PubMed, Clin Cancer Res)

BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.

6 days ago

Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • ETV6 (ETS Variant Transcription Factor 6) • IFNG (Interferon, gamma)

BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • HRAS mutation

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236. (PubMed, Clin Cancer Res)

RRASQ87L and RRAS2Q72L are recurrent, oncogenic, and potentially actionable drivers in NSCLC. Our study supports the inclusion of RRAS/RRAS2 into routine molecular diagnostic panels for precision oncology and provides preclinical rationale for investigating the potential therapeutic utility of pan-RAS inhibitors for patients with RRASQ87L/RRAS2Q72L-mutant lung cancers.

6 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)

NRAS Q61 • KRAS Q61

MSK-IMPACT

daraxonrasib (RMC-6236)

Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation. (PubMed, bioRxiv)

The kinases PAK1 and PAK2 shield RAS from LZTR1-dependent degradation by phosphorylating T148, and targeting PAK1/2 activity improves RAS-directed therapy. Collectively, our findings reveal a novel regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable.

6 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PAK2 (P21 (RAC1) Activated Kinase 2) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)

KRAS mutation • NRAS mutation • KRAS A146 • NRAS A146

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (clinicaltrials.gov)

P1, N=51, Completed, InxMed (Shanghai) Co., Ltd. | Active, not recruiting --> Completed | N=120 --> 51

6 days ago

Trial completion • Enrollment change

NRAS (Neuroblastoma RAS viral oncogene homolog)

NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13

Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)

Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non-Small Cell Lung Cancer in Brazil. (PubMed, JCO Glob Oncol)

This study provides an overview of the genomic landscape of early-stage nonsquamous NSCLC in Brazilian patients. The high prevalence of mutations observed in our cohort underscores the importance of genomic testing in this setting, enabling selection of patients suitable for targeted approved therapies or clinical trials.

7 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation

Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. (PubMed, JCO Precis Oncol)

Our study reveals the preliminary molecular landscape of Chinese pediatric sarcomas, indicating that molecular changes may represent different therapeutic responses and pathologic characteristics may correlate with molecular characteristics, suggesting the need for panel sequencing for pediatric sarcoma.

7 days ago

Journal

TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)

TP53 mutation • KRAS mutation • NRAS mutation

Small Nucleotide Variant Analysis Using RNA Fusion Panel (SMURF): Making the Most of RNAseq Data in Solid Tumours. (PubMed, J Clin Lab Anal)

This analysis suggests that the variants in these genes can be confidently reported from RNA-Seq data obtained from an RNA-based fusion panel.

8 days ago

Journal

NRAS (Neuroblastoma RAS viral oncogene homolog) • GNAQ (G Protein Subunit Alpha Q) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • GNAS (GNAS Complex Locus)

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy. (PubMed, Cell Oncol (Dordr))

These data suggest the potential of the 6-gene Duplex Sequencing assay to improve EGFRi patient selection and therapeutic outcomes.

9 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • APC (APC Regulator Of WNT Signaling Pathway)

TP53 mutation • EGFR mutation • BRAF mutation • NRAS mutation

Translational Suppression of KRAS and NRAS via RNA G-Quadruplex-Targeting Small Molecules for Colorectal Cancer Therapy. (PubMed, J Med Chem)

BYBC-1 showed potent activity against HCT-116 cells (IC50 = 1.09 μM) with >20-fold selectivity over nonmalignant fibroblast cells. In vivo, it reduced tumor weight by 78% in an HCT-116 xenograft mouse model, confirming strong antitumor efficacy.

9 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)

RAS mutation